

- 2 **Doporučený postup ČDS pro léčbu diabetu 2. typu: změny v roce 2016**
prof. MUDr. Milan Kvapil, CSc., MBA Interní klinika FN Motol a 2. LF UK, Praha
- 2 **Srdeční selhání a diabetes mellitus**
doc. MUDr. Jiří Špác, CSc. II. interní klinika FN u sv. Anny, Brno
- 2 **Kontinuální monitorace glukózy u pacientů s režimem bazál-bolus**
MUDr. Jan Šoupal III. interní klinika – klinika endokrinologie a metabolismu, VFN a 1. LF UK, Praha
- 3 **Je třeba snižovat cílové hodnoty krevního tlaku u pacientů s DM po studii SPRINT?**
prof. MUDr. Miroslav Souček, CSc. | MUDr. Ivan Řiháček, Ph.D. | MUDr. Jan Novák II. interní klinika LF MU a ICRC, FN u sv. Anny v Brně
- 3 **Nová orální antikoagulancia u diabetiků**
MUDr. Antonín Novák Ústecká poliklinika, s. r. o., Ústí nad Labem
- 3 **Nové inzuliny a jejich fixní kombinace v diabetologii**
prof. MUDr. Martin Haluzík, DrSc. Endokrinologický ústav a ÚLBDL 1. LF UK a VFN, Praha
- 4 **Význam ezetimibu pro intervenci hyperlipidemie u pacientů s DM**
prof. MUDr. Richard Češka, CSc.
Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 4 **Lixisenatid u osob s diabetem 2. typu a akutním koronárním syndromem (studie ELIXA)**
MUDr. Marek Honka Interní a diabetologická ambulance, Lestela Hlučín, s. r. o.
- 5 **Fixní kombinace empagliflozinu s metforminem – lékový profil**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 5 **Léčba exenatidem LAR (Bydureon) napomohla k úpravě albuminurie u nemocného s diabetickým onemocněním ledvin – kazuistika**
MUDr. Marek Honka Interní a diabetologická ambulance, Lestela Hlučín, s. r. o.
- 5 **Jsou betablokátory stále moderní léky?**
doc. MUDr. Jiří Špác, CSc. II. interní klinika FN u sv. Anny, Brno
- 6 **Digoxin a srdeční selhání**
prof. MUDr. Jiří Vítovec, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC
I. interní kardiologická klinika LF MU a FN u sv. Anny, Brno
- 6 **Blokátory kalciových kanálů**
MUDr. Tomáš Edelsberger Privátní diabetologická ambulance, Krnov
- 6 **„Stará“ a nová antikoagulancia**
doc. MUDr. Petr Heinc, Ph.D. | MUDr. Aleš Smékal | MUDr. Lucie Gajdošová | MUDr. Monika Kamasová | Leo Rec
I. interní klinika – kardiologická, Fakultní nemocnice, Olomouc
- 7 **Kompenzace arteriální hypertenze podle medicíny založené na důkazech aneb v jednoduchosti je síla – kazuistika**
MUDr. Michaela Šnejdrová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 7 **Monoklonální protilátky v preventivní kardiologii**
MUDr. Eva Tůmová | doc. MUDr. Michal Vrablík, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 7 **Fixní dvojkombinace v léčbě arteriální hypertenze se zaměřením na lisinopril/amlodipin (Amesos)**
prof. MUDr. Jiří Widimský jr., CSc. III. interní klinika – Centrum pro hypertenzi VFN a 1. LF UK, Praha
- 8 **Jak můžeme v praxi ověřit komplianci pacienta k antihypertenzní léčbě a jak ji zlepšit**
doc. MUDr. Jan Václavík, Ph.D., FESC Centrum pro hypertenzi, I. Interní klinika – kardiologická, FN a LF UP Olomouc
- 8 **Riziko užívání neopioidních analgetik v kardiologii**
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 8 **Akutní perikarditida v EKG obraze**
MUDr. Kamila Šolcová | MUDr. Pavel Lang Nemocnice Jablonec nad Nisou, p. o.
- 9 **Rosuvastatin – možnost bezpečného a rychlého snížení cholesterolu**
MUDr. Eva Tůmová, Ph.D. | doc. MUDr. Michal Vrablík, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 9 **Fabryho choroba**
MUDr. Lubor Goláň II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Doporučený postup ČDS pro léčbu diabetu 2. typu: změny v roce 2016

prof. MUDr. Milan Kvapil, CSc., MBA Interní klinika FN Motol a 2. LF UK, Praha

- 1 Brož, J. – Honěk, P. – Dušek, L. – Pavlík, T. – Kvapil, M.: The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average. *Vnitřní Léčba*, 2015, 61, s. 14–20.
- 2 Dostupné z: http://www.diab.cz/dokumenty/doporučení_DM_2015-2.pdf, vyhledáno 8. 3. 2016.
- 3 The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the diabetes control and complications trial. *Diabetes*, 1997, 46, s. 271–286.
- 4 The DCCT Research Group: Epidemiology of severe hypoglycemia in the diabetes control and complications trial. *Am J Med*, 1991, 90, s. 450–459.
- 5 Cryer, P. E.: Hypoglycemia in type 1 diabetes mellitus. *Endocrinol Metab Clin North Am*, 2010, 39, s. 641–654.
- 6 McCoy, R. G. – Van Houten, H. K. – Ziegenfuss, J. Y., et al.: Increased mortality of patients with diabetes reporting severe hypoglycemia. *Diabetes Care*, 2012, 35, s. 1897–1901.
- 7 Mannucci, E. – Monami, M. – Marchionni, N.: Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. *Diabetes Obes Metab*, 2009, 11, s. 53–59.
- 8 Siebenhofer, A. – Plank, J. – Berthold, A., et al.: Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. *Cochrane Database Syst Rev*, 19. 4. 2006, CD003287.
- 9 Home, P. D. – Fritsche, A. – Schinzel, S. – Massi-Benedetti, M.: Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. *Diabetes Obes Metab*, 2010, 12, s. 772–779.
- 10 Horváth, K. – Jettler, K. – Berthold, A., et al.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database Syst Rev*, 18. 4. 2007, CD005613.
- 11 Kvapil, M.: Postavení fixní kombinace antidiabetik v terapii. *Remedia*, 2013, 23, s. 2–5.
- 12 Gough, S. C. – Bode, B. – Woo, V., et al.: NN9068-3697 (DUAL-I) trial investigators. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. *Lancet Diabetes Endocrinol*, 2014, 2, s. 885–893.
- 13 Riedel, M. C. – Forst, T. – Aronson, R., et al.: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). *Diabetes Care*, 2013, 36, s. 2497–2503.

Srdeční selhání a diabetes mellitus

doc. MUDr. Jiří Špác, CSc. II. interní klinika FN u sv. Anny, Brno

- 1 Fox, C. – Hill Golden, S. – Anderson, Ch., et al.: Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association. *Diabetes Care*, 2015, 38, s. 1777–1803.
- 2 Control Group, Turnbull, F. M. – Abraira, C., et al.: Intensive glucose control and cardiovascular outcomes in type 2 diabetes. *Diabetologia*, 2009, 52, s. 2288–2298.
- 3 Klieger, R. – Miller, J. – Digger, J. – Moss, A.: Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol*, 1987, 59, s. 256–262.
- 4 Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for industry: diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Prosinec 2008 (<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf>)
- 5 Ferrannini, E. – DeFronzo, R. A.: Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. *EHJ*, 2015, 36, s. 2288–2296.
- 6 Eurich, D. T. – Majumdar, S. R. – McAlister, F. A., et al.: Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. *Diabetes Care*, 2005, 28, s. 2345–2351.
- 7 Pfeffer, M. A. – Claggett, B. – Diaz, R., et al.: Lixisenatid in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*, 2015, 373, 23, s. 2247–2257.
- 8 Holman, R. R. – Sourij, H. – Califf, R. M.: Cardiovascular outcome trials of glucose lowering drugs or strategies in type 2 diabetes. *Lancet*, 2014, 383, s. 2008–2017.
- 9 Scirica, B. M. – Bhatt, D. L. – Braunwald, E., et al.: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*, 2013, 369, s. 1317–1326.
- 10 Špinar, J. – Špinarová, L. – Vitovec J.: EXAMINE – alogliptin po akutním koronárním syndromu u pacientů s diabetem mellitem 2. typu. *Remedia*, 2014, 24, s. 301–304.
- 11 Kvapil, M.: Nové léky v terapii diabetu mellitem 2. typu. *Vnitřní Léčba*, 2013, 59, s. 713–718.
- 12 Zinman, B. – Wanner, C. – Lachin, J. M., et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.

Kontinuální monitorace glukózy u pacientů s režimem bazál-bolus

MUDr. Jan Šoupal III. interní klinika – klinika endokrinologie a metabolismu, VFN a 1. LF UK, Praha

- 1 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The Diabetes Control and Complications Trial (DCCT) Research Group. *N Engl J Med*, 1993, 329, s. 977–986.
- 2 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*, 1998, 352, s. 837–853.
- 3 Rosenwasser R. F. – Sultan, S. – Sutton, D., et al.: SGLT-2 inhibitors and their potential in the treatment of diabetes. *Diabetes Metab Syndr Obes*, 2013, 6, s. 453–467.
- 4 Scheen, A. J.: A review of gliptins in 2011. *Expert Opin Pharmacother*, 2012, 13, s. 81–99.
- 5 Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 2015, 38, s. 140–149.
- 6 Miller, K. M. – Foster, N. C. – Beck, R. W., et al.: T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. *Diabetes Care*, 2015, 38, s. 971–978.
- 7 Šoupal, J. – Škrha, J. Jr. – Fajmon, M., et al.: Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. *Diabetes Technol Ther*, 2014, 16, s. 198–203.
- 8 Haluzík, M., et al.: *Praktická léčba diabetu*. Mladá fronta, 2013.
- 9 Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Effectiveness of continuous glucose monitoring in a clinical care environment: evidence from the Juvenile Diabetes Research Foundation continuous glucose monitoring (JDRF-CGM) trial. *Diabetes Care*, 2010, 33, s. 17–22.
- 10 Bergenstal, R. M. – Tamborlane, W. V. – Ahmann, A., et al.: STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. *N Engl J Med*, 2010, 363, s. 311–320.
- 11 Battelino, T. – Confer, I. – Olsen, B., et al.: SWITCH Study Group. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. *Diabetologia*, 2012, 55, s. 3155–3162.
- 12 Rodbard, D.: Continuous glucose monitoring: A review of successes, challenges, and opportunities. *Diabetes Technol Ther*, 2016, 18, dopl. s. 523–5213.
- 13 Garg, S. K. – Schwarz, S. – Edelman, S. V.: Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. *Diabetes Care*, 2004, 27, s. 734–738.
- 14 Rodbard, D. – Jovanovic, L. – Garg, S.: Responses to continuous glucose monitoring in patients with type 1 diabetes using multiple daily injections and insulin pumps. *Diabetes Technol Ther*, 2009, 11, s. 757–765.
- 15 Saisho, Y.: Glycemic variability and oxidative stress: A link between diabetes and cardiovascular disease? *Int J Mol Sci*, 2014, 15, s. 18381–18406.
- 16 Bailey, T. – Bode, B. W. – Christiansen, M. P., et al.: The performance and usability of a factory-calibrated flash glucose monitoring system. *Diabetes Technol Ther*, 2015, 17, s. 787–794.
- 17 Prázný, M.: Selfmonitoring glykémie a přesnost glukometrů. *Interní Med*, 2013, 15, s. 206–209.
- 18 Garg, S. K. – Voelmie, M. K. – Beatson, C. R., et al.: Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. *Diabetes Care*, 2011, 34, s. 574–579.
- 19 Deiss, D. – Bolinder, J. – Riveline, J. P., et al.: Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. *Diabetes Care*, 2006, 29, s. 2730–2732.
- 20 Pickup, J. C. – Freeman, S. C. – Sutton, A. J.: Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. *BMJ*, 2011, 343, s. d3805.
- 21 Tamborlane, W. V. – Beck, R. W. – Bode, B. W., et al.: Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *N Engl J Med*, 2008, 359, s. 1464–1476.
- 22 Tuminia, A. – Crimi, S. – Sciacca, L., et al.: Efficacy of real-time continuous glucose monitoring on glycaemic control and glucose variability in type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy: a randomized controlled crossover trial. *Diabetes Metab Res Rev*, 2015, 31, s. 61–68.
- 23 Šoupal, J. – Flekač, M. – Petruželová, L. – Škrha, J. Jr. – Škrha, J. – Prázný, M.: Continuous glucose monitoring improved glycemic control in patients with type 1 diabetes during 52 weeks of insulin pump therapy as well as with basal-bolus insulin regimen. Prezentováno na EASD 2015.
- 24 Steinech, I. – Cederholm, J. – Eliasson, B., et al.: Swedish National Diabetes Register. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. *BMJ*, 2015, 350, s. h3234.

Je třeba snižovat cílové hodnoty krevního tlaku u pacientů s DM po studii SPRINT?

prof. MUDr. Miroslav Souček, CSc. | MUDr. Ivan Řiháček, Ph.D. | MUDr. Jan Novák

II. interní klinika LF MU a ICRC, FN u sv. Anny v Brně

- Cushman, W. C. – Evans, G. W. – Byington, R. P., et al.: ACCORD Study Group. Effect of intensive blood pressure control in type 2 diabetes mellitus. *N Engl J Med*, 2010, 373, s. 2180–2182.
- Filipovský, J. – Widimský, J. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. *Hypertenze a kardiovaskulární prevence*, 2013, 3, s. 1–15.
- Franclin, S. S. – Jacobs, M. J. – Wong, N. D., et al.: Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. *Hypertension*, 2001, 37, s. 869–874.
- Chobanian, A. V. – Bakris, G. L. – Black, H. R., et al.: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 Report. *JAMA*, 2003, 289, s. 2560–2572.
- Hsu, C. Y. – McCulloch, C. E. – Darbinian, J., et al.: Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. *Arch Intern Med*, 2005, 165, s. 923–928.
- Sundström, J. – Arima, H. – Jackson, R., et al.: Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. *Ann Intern Med*, 2015, 162, s. 184–191.
- Neal, B. – MacMahon, S. – Chapman, N.: Effects of ACE inhibitors, calcium antagonists, and other blood pressure – lowering drugs: results of prospectively designed overview of randomised trials. *Lancet*, 2000, 356, s. 1955–1964.
- Psaty, B. M. – Smith, N. L. – Siscovick, D. S., et al.: Health outcomes associated with antihypertensive therapies used as first-line agents: systematic review and meta-analysis. *JAMA*, 1997, 277, s. 739–745.
- Lewington, S. – Clarke, R. – Qizilbash, N., et al.: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*, 2002, 360, s. 1903–1913.
- Beckett, N. S. – Peters, R. – Fletcher, A. E., et al.: Treatment of hypertension in patients 80 years of age or older. *N Engl J Med*, 2008, 358, s. 1887–1898.
- Verdecchia, P. – Staessen, J. A. – Angeli, F., et al.: Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (CardioSis): a open-label randomised trial. *Lancet*, 2009, 374, s. 525–533.
- Wright, J. T. – Williamson, P. K. – Snyder, J. K., et al.: A randomised trial of intensive versus standard blood-pressure control. The SPRINT Group. *N Engl J Med*, 2015, 373, s. 2103–2116.
- Peckovic, V. – Rodgers, A.: Redefining blood-pressure targets – SPRINT starts the marathon. *N Engl J Med*, 2015, 373, s. 2175–2178.
- Drazen, J. M. – Morrissey, S. – Campion, E. W. – Jarcho, J. A.: A SPRINT to the finish. *N Engl J Med*, 2015, 373, s. 2174–2175.
- Souček, M. – Widimský, J. – Lánská, V.: Control of hypertension in patients with hypertension, diabetes a impaired fasting glucose by Czech primary care physicians. *Kidney and Blood Pressure*, 2006, 29, s. 366–372.
- Cushman, W. C. – Evans, G. W. – Cutler, J. A.: Long-term cardiovascular effects of 4.9 years of intensive blood pressure control in type 2 diabetes mellitus: The Action to Control Cardiovascular Risk in Diabetes: follow-on blood-pressure study. American Heart Association 2015 Scientific Sessions, 10. 11. 2015, Orlando, FL, abstrakt.

Nová orální antikoagulantia u diabetiků

MUDr. Antonín Novák Ústecká poliklinika, s. r. o., Ústí nad Labem

- Neuwalaar, R. – Capucci, A. – Camm, A. J., et al.: Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation. ISAF study. *Am J Cardiol*, 2013, 111, s. 705–711.
- Huxley, R. R. – Filion, K. B. – Konety, S., et al.: Meta-analysis of cohort and case control studies of type 2 diabetes mellitus and risk of atrial fibrillation. *Am J Cardiol*, 2011, 108, s. 1501–1508.
- Stroke Risk in Atrial Fibrillation Working Group: Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. *Stroke*, 2008, 39, s. 1901–1910.
- Tuornilehto, J. – Rastenyte, D. – Jouslahti, P., et al.: Diabetes mellitus as a risk factor for death from stroke. Prospective study of middle-aged Finnish population. *Stroke*, 1996, 27, s. 210–215.
- Oldgren, J., et al.: Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS₂ Score: A subgroup analysis of the RE-LY trial. *Ann Int Med*, 2011, 155, s. 660–667.
- Camm, A. J. – Amarencio, P. – Haas, S., et al.: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J*, 1. 9. 2015, pii: ehv466.
- Tomek, A. – Matuška, V.: Jak proč vůbec léčit warfarinem. *Causa subtila*, 2012, 5.
- Witt, D. M. – Delate, T. – Clark, N. P., et al.: Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. *Blood*, 2009, 114, s. 952–956.
- Spinar, J., et al.: Profile of Czech AF 2012; Profile of AF patients receiving antithrombotic therapy. *Cor et Vasa*, 2014, 56, s. 207–216.
- Novák, A. – Kallimünzerová, D. – Nguyen, H., et al.: Elektrická kardiaverze u pacientů s fibrilací síní. Roční retrospektivní studie, posterové sdělení, kongres České internistické společnosti, Praha 2014.

Nové inzulinové a jejich fixní kombinace v diabetologii

prof. MUDr. Martin Haluzík, DrSc. Endokrinologický ústav a ÚLBDL 1. LF UK a VFN, Praha

- O'Rahilly, S.: Science, medicine, and the future. Non-insulin dependent diabetes mellitus: the gathering storm. *BMJ*, 1997, 314, s. 955–959.
- Škřha, J. – ČDS Zv.: Diabetes mellitus 2002 v ČR – epidemiologická studie. *DMEV*, 2005, 8, s. 5–12.
- Reaven, G. – Abbasi, F. – McLaughlin, T.: Obesity, insulin resistance, and cardiovascular disease. *Recent progress in hormone research*, 2004, 59, s. 207–223.
- Svačina, S. – Owen, K.: *Syndrom inzulinové rezistence*. Praha, Triton, 2003.
- Haffner, S. M. – Lehto, S. – Ronnema, T., et al.: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *New Eng J Med*, 1998, 339, s. 229–234.
- Holman, R. R. – Paul, S. K. – Betel, M. A., et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. *New Eng J Med*, 2008, 359, s. 1577–1589.
- Calvert, M. J. – McManus, R. J. – Freemantle, N.: Management of type 2 diabetes with multiple oral hypoglycaemic agents or insulin in primary care: retrospective cohort study. *Br J Gen Pract*, 2007, 57, s. 455–460.
- Simons, W. R. – Vinod, H. D. – Gerber, R. A. – Bolinder, B.: Does rapid transition to insulin therapy in subjects with newly diagnosed type 2 diabetes mellitus benefit glycaemic control and diabetes-related complications? A German population-based study. *Exp Clin Endocrinol Diabetes*, 2006, 114, s. 520–526.
- Gauner, T. A.: Managing older adults with diabetes. *J Am Acad Nurse Pract*, 2006, 18, s. 309–317.
- Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 2015, 38, s. 140–149.
- Jensen, M. G. – Hansen, M. – Brock, B., et al.: Differences between long-acting insulins for the treatment of type 2 diabetes. *Exp Op Pharm*, 2010, 11, s. 2027–2035.
- Sutton, G. – Minguet, J. – Ferrero, C., et al.: U300, a novel long-acting insulin formulation. *Exp Op Biol Ther*, 2014, 14, s. 1849–1860.
- Bergenstal, R. M. – Rosenstock, J. – Arakaki, R. F., et al.: A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. *Diabetes Care*, 2012, 35, s. 2140–2147.
- Rosenstock, J. – Bergenstal, R. M. – Blevins, T. C., et al.: Better glycaemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. *Diabetes Care*, 2013, 36, s. 522–528.
- Goldman-Levine, J. D. – Patel, D. K. – Schnee, D. M.: Insulin degludec: a novel basal insulin analogue. *An Pharm*, 2013, 47, s. 269–277.
- Birkeland, K. I. – Raz, I. – Gough, S., et al.: Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes. *Diabetologia*, 2011, 60, dopl. 1A, s. LB10–LB11.
- Dardano, A. – Bianchi, C. – Del Prato, S., et al.: Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes. *Vasc Health Risk Manag*, 2014, 10, s. 465–475.
- Havelund, S. – Ribel, U. – Hubalek, F., et al.: Investigation of the physico-chemical properties that enable co-formulation of basal insulin degludec with fast-acting insulin aspart. *Pharm Res*, 2015, 32, s. 2250–2258.
- Franek, E. – Haluzík, M. – Canecki Varnic, S., et al.: Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes. *Diabet Med*, 4. 10. 2015, doi: 10.1111/dme.12982.
- Onishi, Y. – Ono, Y. – Rabol, R., et al.: Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. *Diabetes, Obesity & Metabolism*, 2013, 15, s. 826–832.
- Raz, I. – Wilson, P. W. – Strojek, K., et al.: Effects of prandial versus fasting glycaemia on cardiovascular outcomes in type 2 diabetes: the HEART 2D trial. *Diabetes Care*, 2009, 32, s. 381–386.
- Doggrell, S. A.: Is liraglutide or exenatide better in type 2 diabetes? *Exp Op Pharm*, 2009, 10, s. 2769–2772.
- Buse, J. B. – Bergenstal, R. M. – Glass, L. C., et al.: Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. *An Int Med*, 2011, 154, s. 103–112.
- Christensen, M. – Knop, F. K. – Vilsboll, T. – Holst, J. J.: Lixisenatide for type 2 diabetes mellitus. *Exp Op Invest Drugs*, 2011, 20, s. 549–557.
- Riedle, M. C. – Aronson, R. – Home, P., et al.: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*, 2013, 36, s. 2489–2496.

- 26 Riedle, M. C. – Forst, T. – Aronson, R., et al.: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). *Diabetes Care*, 2013, 36, s. 2497–2503.
- 27 DeVries, J. H. – Bain, S. C. – Rodbard, H. W., et al.: Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. *Diabetes Care*, 2012, 35, s. 1446–1454.
- 28 Mathieu, C. – Rodbard, H. W. – Cariou, B., et al.: A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN-VICTOZA ADD-ON). *Diabetes, Obesity & Metabolism*, 2014, 16, s. 636–644.
- 29 Morales, J. – Merker, L.: Minimizing hypoglycemia and weight gain with intensive glucose control: potential benefits of a new combination therapy (IDegLira). *Advan Ther*, 2015, 32, s. 391–403.
- 30 Buse, J. B. – Gough, S. C. – Woodward, M., et al.: IDegLira, a novel fixed ratio combination of insulin degludec and liraglutide, is efficacious and safe in subjects with type 2 diabetes: a large, randomized phase 3 trial. *Diabetes Care*, 2013, 36, s. A16.
- 31 Buse, J. B. – Han, J. – Miller, S., et al.: Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titration. *Cur Med Res Op*, 2014, 30, s. 1209–1218.

Význam ezetimibu pro intervenci hyperlipidemie u pacientů s DM

prof. MUDr. Richard Češka, CSc.

Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 Češka, R., et al.: *Familiární hypercholesterolemie*. TRITON, Praha, 2015.
- 2 Gæde, P. – Lund-Andersen, H. – Parving, H. H. – Pedersen, O.: Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med*, 2008, 358, s. 580–591.
- 3 Sedlis, S. P. – Hartigan, P. M. – Teo, K. K., et al.: Effect of PCI on long-term survival in patients with stable ischemic heart disease. *N Engl J Med*, 2015, 373, s. 1937–1946.
- 4 Robinson, J. G. – Farnier, M. – Krempf, M., et al.: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1489–1499.
- 5 Sabatine, M. S. – Giugliano, R. P. – Wiviott, S. D., et al.: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1500–1509.
- 6 Raal, F. J. – Giugliano, R. P. – Sabatine, M. S., et al.: Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol*, 2014, 63, s. 1278–1288.
- 7 Nordestgaard, B. G. – Chapman, M. J. – Humphries, S. E., et al.: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J*, 2013, 34, s. 3478–3490.
- 8 Watts, G. F. – Gidding, S. – Wierzbicki, A. S., et al.: Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. *Int J Cardiol*, 2014, 171, s. 309–325.
- 9 Jimenez, J. G. – Rosen, J. B. – Pirags, V., et al.: The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. *Diabetes, Metabolism and Obesity*, 2013, 15, s. 513–522.
- 10 Canon, Ch. P. – Blazing, M. A. – Giugliano, R. P., et al.: for the IMPROVE-IT investigators: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.
- 11 Reiner, Z. – Catapano, A. L. – De, B. G., et al.: ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J*, 2011, 32, s. 1769–1818.
- 12 Standards of medical care in diabetes – 2013. *Diabetes Care*, 2013, 36, suppl. 1, s. S11–S66.
- 13 Chapman, M. J. – Ginsberg, H. N. – Amarencu, P., et al.: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J*, 2011, 32, s. 1345–1361.
- 14 Ginsberg, H. N. – Elam, M. B. – Lovato, L. C., et al.: Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med*, 2010, 362, s. 1563–1574.
- 15 Sattar, N.: Revisiting the links between glycaemia, diabetes and cardiovascular disease. *Diabetologia*, 2013, 56, s. 686–695.
- 16 Wannamethee, S. G. – Shaper, A. G. – Whincup, P. H., et al.: Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. *Arch Intern Med*, 2011, 171, s. 404–410.
- 17 Pedersen, T. R. – Faergeman, O. – Kastelein, J. J., et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA*, 2005, 294, s. 2437–2445.
- 18 Waters, D. D. – Ho, J. E. – Boekholdt, S. M., et al.: Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. *J Am Coll Cardiol*, 2013, 61, s. 148–152.
- 19 Watts, G. F. – Ooi, E. M.: Balancing the cardiometabolic benefits and risks of statins. *Lancet*, 2012, 380, s. 541–543.
- 20 Young, F. – Capewell, S. – Ford, E. S., et al.: Coronary mortality declines in the U.S. between 1980 and 2000 quantifying the contributions from primary and secondary prevention. *Am J Prev Med*, 2010, 39, s. 228–234.

Lixisenatid u osob s diabetem 2. typu a akutním koronárním syndromem (studie ELIXA)

MUDr. Marek Honka Interní a diabetologická ambulance, Lestela Hlučín, s. r. o.

- 1 The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med*, 1993, 329, s. 977–986.
- 2 The UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet*, 1998, 352, s. 854–865.
- 3 The UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *Lancet*, 1998, 352, s. 837–853.
- 4 Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. *N Engl J Med*, 2003, 348, s. 2294–2303.
- 5 Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med*, 2005, 353, s. 2643–2645.
- 6 The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*, 2008, 358, s. 2545–2559.
- 7 The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*, 2008, 358, s. 2560–2572.
- 8 Abraira, C. – Duckworth, W. C. – Moritz, T.: Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. *Diabetes Obes Metab*, 2009, 11, s. 150–156, Epub 29. 7. 2008.
- 9 Ray, K. K. – Seshasai, S. R. – Wijesuriya, S., et al.: Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomized controlled trials. *Lancet*, 2009, 373, s. 1765–1772.
- 10 Kelly, T. N. – Bazzano, L. A. – Fonseca, V. A., et al.: Systematic review: glucose control and cardiovascular disease in type 2 diabetes. *Ann Intern Med*, 2009, 151, s. 394–403.
- 11 Lago, R. M. – Singh, P. P. – Nesto, R. W.: Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. *Lancet*, 2007, 370, s. 1129–1136.
- 12 *Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes*. Silver Spring, MD: Department of Health and Human Services, Center for Drug Evaluation and Research, 2008.
- 13 *European Medicines Agency guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus*. London, Committee for Medicinal Products for Human Use, 2012.
- 14 Drucker, D. J.: The biology of incretin hormones. *Cell Metab*, 2006, 3, s. 153–165.
- 15 Noyan-Ashraf, M. H. – Momen, M. A. – Ban, K., et al.: GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. *Diabetes*, 2009, 58, s. 975–983.
- 16 Timmers, L. – Henriques, J. P. – de Klein, D. P., et al.: Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. *J Am Coll Cardiol*, 2009, 53, s. 501–510.
- 17 Fonseca, V. A. – Alvarado-Ruiz, R. – Raccach, D., et al.: Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo controlled trial in patients with type 2 diabetes (GetGoal-Mono). *Diabetes Care*, 2012, 35, s. 1225–1231.
- 18 Bolli, G. B. – Munteanu, M. – Dotsenko, S., et al.: Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). *Diabet Med*, 2014, 31, s. 176–184.
- 19 Riedle, M. C. – Aronson, R. – Home, P., et al.: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*, 2013, 36, s. 2489–2496.
- 20 Bentley-Lewis, R. – Aguilar, D. – Riedle, M. C., et al.: Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. *Am Heart J*, 2015, 169, s. 631–638.
- 21 Pfeffer, M. A. – Claggett, B. – Diaz, R., et al.: The evaluation of lixisenatide in acute coronary syndrome. *N Engl J Med*, 2015, 373, s. 2247–2257.
- 22 Wing, R. R. – Bolin, P. – Brancati, F. L., et al.: Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med*, 2013, 369, s. 145–154.
- 23 Holman, R. R. – Paul, S. K. – Betel, M. A., et al.: 10-Year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*, 2008, 359, s. 1577–1589.
- 24 Hayward, R. A. – Reaven, P. D. – Witala, W. L., et al.: Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*, 2015, 372, s. 2197–2206.

Fixní kombinace empagliflozinu s metforminem – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Ehrenkranz, J. R. – Lewis, N. G. – Kahn, C. R. – Roth, J.: Phlorizin: a review. *Diabetes Metab Res Rev*, 2005, 21, s. 31–38.
- 2 Lewin, A. J. – Trias, J. P.: Empagliflozin added to metformin and sulfonylurea therapy in patients with sub-optimally controlled type 2 diabetes mellitus. *Expert Opin Pharmacother*, 2015, 16, s. 781–784.
- 3 Saenz, A. – Fernandez-Esteban, I. – Mataix, A., et al.: Metformin monotherapy for type 2 diabetes mellitus. *Cochrane Database Syst Rev*, 2005, CD002966.
- 4 Formoso, G. – De Filippis, E. A. – Michetti, N., et al.: Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects. *Diabetes Metab Res Rev*, 2008, 24, s. 231–237.
- 5 Detaile, D. – Guigas, B. – Chauvin, C., et al.: Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process. *Diabetes*, 2005, 54, s. 2179–2187.
- 6 Scarpello, J. H. – Hewlett, H. C.: Metformin therapy and clinical uses. *Diab Vasc Dis Res*, 2008, 5, s. 157–167.
- 7 Scheen, A. J.: Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. *Clin Pharmacokinet*, 2014, 53, s. 213–225.
- 8 Ferrannini, E. – Muscelli, E. – Frascerra, S., et al.: Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest*, 2013, 124, s. 499–508.
- 9 Rojas, C. – Link, J. – Meinicke, T. – Macha, S.: Pharmacokinetics of fixed-dose combinations of empagliflozin/metformin compared with individual tablets in healthy subjects. *Int J Clin Pharmacol Ther*, 2016, v tisku.
- 10 Sarashina, A. – Koiwai, K. – Seman, L. J., et al.: Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects. *Drug Metab Pharmacokinet*, 2013, 28, s. 213–219.
- 11 Macha, S. – Jungnik, A. – Hohl, K., et al.: Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers. *Int J Clin Pharmacol Ther*, 2013, 51, s. 873–879.
- 12 Arnouts, P. – Boignano, D. – Nistor, I., et al.: Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. *Nephrol Dial Transplant*, 2014, 29, s. 1284–1300.
- 13 Macha, S. – Rose, P. – Mattheus, M., et al.: Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment. *Diabetes Obes Metab*, 2014, 16, s. 118–123.
- 14 Macha, S. – Mattheus, M., et al.: Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment. *Diabetes Obes Metab*, 2014, 16, s. 215–222.
- 15 Rosenstock, J. – Seman, L. J., et al.: Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. *Diabetes Obes Metab*, 2013, 15, s. 1154–1160.
- 16 Ridderstrale, M. – Andersen, K. R. – Keller, C., et al.: Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. *Lancet Diabetes Endocrinol*, 2014, 2, s. 691–700.
- 17 Ferrannini, E. – Berk, A., et al.: Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. *Diabetes Care*, 2013, 36, s. 4015–4021.
- 18 Häring, H. U. – Merker, L. – Seewaldt-Becker, E., et al.: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care*, 2014, 37, s. 1650–1659.
- 19 Häring, H. U. – Merker, L. – Seewaldt-Becker, E., et al.: Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. *Diabetes Care*, 2013, 36, s. 3396–3404.
- 20 Kovacz, C. S. – Seshiah, V. – Swallow, R., et al.: Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. *Diabetes Obes Metab*, 2014, 16, s. 147–158.
- 21 Zinman, B. – Wanner, C., et al.: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med*, 2015, 373, s. 2117–2128.
- 22 Ross, S. – Hamer, C. – Cescutti, J., et al.: Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial. *Diabetes Obes Metab*, 2015, 17, s. 699–702.
- 23 Merker, L. – Häring, H. U. – Christiansen, A. V., et al.: Empagliflozin as add-on to metformin in people with Type 2 diabetes. *Diabet Med*, 2015, 32, s. 1555–1567.
- 24 Haering, H. U. – Merker, L. – Christiansen, A. V., et al.: Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. *Diabetes Res Clin Pract*, 2015, 110, s. 82–90.
- 25 Zhong, X. – Lai, D. – Ye, Y., et al.: Efficacy and safety of empagliflozin as add-on to metformin for type 2 diabetes: a systematic review and meta-analysis. *Eur J Clin Pharmacol*, 2016, v tisku.

Léčba exenatidem LAR (Bydureon) napomohla k úpravě albuminurie u nemocného s diabetickým onemocněním ledvin – kazuistika

MUDr. Marek Honka Interní a diabetologická ambulance, Lestela Hlučín, s. r. o.

- 1 Bunck, M. C. – Diamant, M. – Eliasson, B., et al.: Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. *Diabetes Care*, 2010, 33, s. 1734–1737.

Jsou betablokátory stále moderní léky?

doc. MUDr. Jiří Špác, CSc. II. interní klinika FN u svaté Anny, Brno

- 1 Powell, C.E. – Slatter, I.H.: Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. *J Pharmacol Exp Ther*, 1958, 124, s. 223.
- 2 Řiháček, I. – Souček, M. – Frána, P.: Betablokátory v léčbě kardiaskulárních onemocnění. *Medicina pro praxi*, 2005, 2, s. 58–61.
- 3 Bangalore, S. – Makani, H. – Radford, M., et al.: Clinical outcomes with β -blockers for myocardial infarction: a meta-analysis of randomized trials. *Am J Med*, 2014, 127, s. 939–953.
- 4 Widimský, P. – Kala, P. – Rokyta, R.: Souhrn Doporučených postupů ESC pro diagnostiku a léčbu pacientů s akutním infarktem myokardu s elevací úseku ST z roku 2012. Přípraven Českou kardiologickou společností. *Cor Vasa*, 2012, 54, s. 447–463.
- 5 Seronde, M. F. – Geha, R. – Puymirat, E., et al.: Discharge heart rate and mortality after acute myocardial infarction. *Am J Med*, 2014, 127, s. 954–962.
- 6 Misumida, N. – Harjai, K. – Kernis, S. – Kanei, Y.: Does oral beta-blocker therapy improve long-term survival in ST-segment elevation myocardial infarction with preserved systolic function? A meta-analysis. *J Cardiovasc Pharmacol Ther*, 29, 9, 2015.
- 7 Bangalore, S. – Bhatt, D. L. – Steg, P. G., et al.: β -blockers and cardiovascular events in patients with and without myocardial infarction. Post hoc analysis from the CHARISMA trial. *Circ Cardiovasc Qual Outcomes*, 2014, 7, s. 872–881.
- 8 Ozasa, N. – Morimoto, T. – Bao, B., et al.: CREDO-Kyoto Registry Investigators. β -blocker use in patients after percutaneous coronary interventions: one size fits all? Worse outcomes in patients without myocardial infarction or heart failure. *Int J Cardiol*, 2013, 168, s. 774–779.
- 9 Dubrava, J.: Prieskum „3P při srdcovom zlyhávani“ so zameraním na srdcovú frekvenciu. *Vnitr Léč*, 2016, 62, s. 17–24.
- 10 Vitovec, J. – Špinar, J.: Beta-blockers in the treatment of chronic heart failure. How should results of clinical studies be introduced into clinical practice. *Vnitr Léč*, 2000, 46, s. 161–165.
- 11 Rienstra, M. – Daman, K. – Mulder, B. A., et al.: Beta blockers and outcome in heart failure and atrial fibrillation: A meta-analysis. *JCHF*, 2013, 1, s. 21–28.
- 12 Kotech, D. – Holme, J. – Krum, H., et al.: Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. *Lancet*, 2014, 384, s. 2235–2243.
- 13 Nielsen, P. B. – Larsen, T. B. – Gorst-Rasmussen, A., et al.: Beta-blockers in atrial fibrillation patients with or without heart failure: insights from a nationwide cohort. Kongres ESC, abstrakt 365, 2015.
- 14 Lund, L. – Benson, L. – Dahlstrom, U., et al.: Association between use of β -blockers and outcomes in patients with heart failure and preserved ejection fraction. *JAMA*, 2014, 312, s. 2008–2018.
- 15 Mason, J. W.: A comparison of seven anti-arrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic study versus Electrocardiographic monitoring (ESVEM) investigators. *N Engl J Med*, 1993, 329, s. 452–458.
- 16 Priori, S. G. – Blomström-Lundqvist, C. – Mazzanti, A., et al.: on behalf of Authors/Task Force Members: 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *European Heart Journal*, 2015, 36, s. 2793–2867.
- 17 Bradley, H. A. – Wiysonge, C. S. – Vilmino, J. A., et al.: How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. *J Hypertens*, 2006, 24, s. 2131–2141.
- 18 Lindholm, L. H. – Carlberg, B. – Samuelsson, O.: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet*, 2005, 366, s. 1545–1553.
- 19 UK National Institute for Health and Clinical Excellence and British Hypertension Society. Hypertension: management of hypertension in adults in primary care. 2006. *NICE guidelines*.
- 20 Boutouyrie, P. – Bussy, C. – Hayoz, D., et al.: Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. *Clinical Investigation and Reports*, 2000, 101, s. 2601–2606.

Digoxin a srdeční selhání

prof. MUDr. Jiří Vítovec, CSc., FESC | prof. MUDr. Lenka Špinarová, Ph.D., FESC
I. interní kardiologická klinika LF MU a FN u svaté Anny, Brno

- 1 **Withering, W.**: *An account of the foxglove and some of its medical uses, with practical remarks on dropsy, and other diseases.* Birmingham, Anglie, M. Swinney, 1785, X, V.
- 2 **Weisse, A. B.**: A fond farewell to the foxglove? The decline in the use of digitalis. *J Cardiac Failure*, 2010, 16, s. 45–47.
- 3 **Švec, F. – Bergmann, K.**: *Srdeční glykosidy*. SPOFA, 1965, s. 140.
- 4 **Erdmann, E. – Greeff, K. – Skou, J. C., et al.**: *Cardiac glycosides 1785–1985.* Springer Verlag Darmstadt, 1986, s. 552.
- 5 **Bada, V.**: Digitalis. *Cardiol*, 2007, 16, s. 49–52.
- 6 **Riečanský, I.**: Digitalis – minulost, přítomnost a perspektivy starého lieku. *Cardiol*, 2007, 16, s. 53–63.
- 7 **Švejda, J.**: Digitalis dnes: zúžené a zpřesněné indikace omezují výskyt toxických projevů. *Kapitol Kardiol*, 2001, 3, s. 106–108.
- 8 **Hradec, J.**: Digoxin v léčbě chronického srdečního selhání. Argumenty pro a proti. *Kapitol Kardiol*, 2002, 4, s. 82–87.
- 9 **Sedloň, P. – Kotík, I.**: Digoxin a jeho užití na počátku dvacátého prvního století. *Interní medicína*, 2002, 3, s. 123–125.
- 10 **Durdil, V.**: Digoxin a jeho užití v klinické praxi. *Remedia*, 2003, 13, s. 135–141.
- 11 **Schatzmann, H. J.**: Cardiac glycosides as inhibitors of active potassium and sodium transport by erythrocyte membrane. *Helv Pharmol Acta*, 11, 1953, s. 346–354.
- 12 **Glynn, I. M.**: The action of cardiac glycosides on sodium and potassium movements in human red cells. *J Physiol*, 1957, 136, s. 148–173.
- 13 **Gheorghade, M. – Ferguson, D.**: Digoxin. A neurohormonal modulator in heart failure? *Circulation*, 1991, 84, s. 2181–2186.
- 14 **Wasserstrom, J. A. – Aistrup, G. L.**: Digitalis: new actions for an old drug. *Am J Physiol Heart Circ Physiol*, 2005, 289, s. H1781–1793.
- 15 **Špinar, J. – Vítovec, J. – Hradec, J., et al.**: Doporučení pro diagnostiku a léčbu chronického srdečního selhání – ČKS 2011. *Cor Vasa*, 2012, 54, s. 161–182.
- 16 **McMurray, J. J. – Adamopoulos, S. – Anker, S. D., et al.**: ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. *Eur Heart J*, 2012, 33, s. 1787–1847.
- 17 **ACCF/AHA, Yancy, C. W. – Jessup, M. – Bozkurt, B., et al.**: ACCF/AHA heart failure guideline for the management of heart failure. *J Amer Coll Cardiol*, 2013, 62, s. e147–239.
- 18 **The Digitalis Investigation Group**: The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med*, 1997, 336, s. 525–533.
- 19 **Yang, E. H. – Shah, S. – Criley, J. M.**: Digitalis toxicity: A fading but crucial complication to recognize. *Amer J Med*, 2012, 125, s. 337–343.
- 20 **Ma, G. – Brady, W. J. – Pollack, M. – Chan, T. C.**: Electrocardiographic manifestations: digitalis toxicity. *J Emerg Med*, 2001, 20, s. 145–152.
- 21 **Shih-Wei, L. – Cheng-Li, L. – Kuan-Fu, L.**: Digoxin use may increase the relative risk of acute pancreatitis: A population-based case-control study in Taiwan. *Int J Cardiol*, 2015, 181, s. 235–238.
- 22 **Lee, T. C.**: Van Gogh's vision. Digitalis intoxication? *JAMA*, 1981, 245, s. 727–729.
- 23 **Gheorghade, M. – Veldhuisen, D. J. – Colucci, W. S.**: Contemporary use of digoxin in the management of cardiovascular disorders. *Circulation*, 2006, 113, s. 2556–2564.
- 24 **Whitbeck, M. G. – Charnigo, R. J. – Khairy, P., et al.**: Increased mortality among patients taking digoxin—analysis from the AFFIRM study. *Eur Heart J*, 2013, 34, s. 1481–1498.
- 25 **Turakhia, M. P. – Santangeli, P. – Winkelmayer, W. C., et al.**: Increased mortality associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF study. *J Am Coll Cardiol*, 2014, 64, s. 660–668.
- 26 **Murphy, S. A.**: When 'digoxin use' is not the same as 'digoxin use': lessons from the AFFIRM trial. *Eur Heart J*, 2013, 34, s. 1465–1467.
- 27 **Rahimtoola, S. H.**: Digitalis therapy for patients in clinical heart failure. *Circulation*, 2004, 109, s. 2942–2946.
- 28 **Ambrosy, A. P. – Butler, J. – Ahmed, A., et al.**: The use of digoxin in patients with worsening chronic heart failure. Reconsidering an old drug to reduce hospital admissions. *J Am Coll Cardiol*, 2014, 63, s. 1823–1832.

Blokátory kalciových kanálů

MUDr. Tomáš Edelsberger Privátní diabetologická ambulance, Krnov

- 1 **Rimoldi, S.**: Efficacy and safety of calcium channel blocker/diuretics combination therapy in hypertensive patients: A meta-analysis. *J Clin Hypertens (Greenwich)*, 2015, 17, s. 193–199, DOI: 10.1111/jch.12462.
- 2 **Sica, D. A.**: Pharmacotherapy review: Calcium channel blockers. *J Clin Hypertens*, 2006, 8, s. 53–56.
- 3 **Špinar, J., et al.**: Kombinační léčba hypertenze 2015. *Vnitřní Léčba*, 2015, 61, s. 458–465.
- 4 **Gregor, P.**: Blokátory vápníkových kanálů a jejich současné místo v kardiologii. *Remedia*, 2011, 2.
- 5 **Noto, H. – Goto, A. – Tsjimoto, T. – Noda, M.**: Effect of calcium channel blockers on incidence of diabetes: a meta-analysis. *Diabetes Metab Syndr Obes*, 2013, 6, s. 257–261.
- 6 **Peters, R. – Booth, B. – Peters, J.**: A systematic review of calcium channel blocker use and cognitive decline/dementia in the elderly. *J Hypertens*, 2014, 32, s. 1945–1958.
- 7 **Lu, Z. – Chen, Y. – Li, L., et al.**: Combination therapy of renin-angiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. *J Hum Hypertens*, 2016, doi:10.1038/jhh.2015.125.
- 8 **Dahlöf, B. – Sever, P. S. – Poulter, N. R.**: ASCOT Investigators: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 9 **Toth, K.**: PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drugs*, 2014, 14, s. 137–145. Erratum in: *Am J Cardiovasc Drug*, 2014, 14, s. 239.
- 10 **Česká společnost pro hypertenzi.** Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. *Hypertenze a kardiologická prevence*, 2012, 3.
- 11 **Špinar, J. – Vítovec, J.**: Postavení blokátorů kalciových kanálů v léčbě hypertenze. *Farmakoterapie*, 2012, 4.
- 12 **Godfraind, T.**: Calcium channel blockers in cardiovascular pharmacotherapy. *J Cardiovasc Pharm Ther*, 2014, s. 501–515.
- 13 **Volpe, M. – Tocci, G.**: Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. *Vascular Health and Risk Management*, 2012, 8, s. 371–380, doi:10.2147/VHRM.S28359.
- 14 **Filipovský, J., et al.**: Summary of 2013 ESH/ESC Guidelines for the management of arterial hypertension. Prepared by the Czech Society of Hypertension/ Czech Society of Cardiology. *Cor et Vasa*, 2014, 56, s. e494–e518.
- 15 **Umamoto, S., et al.**: Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial. *Hypertens Res*, 2013, 36, s. 1088–1095, doi: 10.1038/hr.2013.100, Epub 29. 8. 2013.

„Stará“ a nová antikoagulanca

doc. MUDr. Petr Heinc, Ph.D. | MUDr. Aleš Smékal | MUDr. Lucie Gajdošová |
MUDr. Monika Kamasová | Leo Rec I. interní klinika – kardiologická, Fakultní nemocnice, Olomouc

- 1 **Wardrop, D. – Keeling, D.**: The story of the discovery of heparin and warfarin. *BJH*, 2008, 141, s. 757–763.
- 2 **Salem, D. N. – Stein, P. D. – Al-Ahmad, A., et al.**: Antithrombotic therapy in valvular heart disease—native and prosthetic. The seventh ACCP conference on antithrombotic and thrombolytic therapy. *CHEST*, 2004, 126, s. 4575–4825.
- 3 **Rosický, J.**: Ovlivnění srážení krve se zvláštním zřetelem ke kumarinovým derivátům. *Čas Lék Česk*, 1944, 83, s. 1200.
- 4 **Perlík, F. – Patzelová, V.**: Pharmacokinetics of ethyl biscoumacetate and its metabolite 7-hydroxy ethyl biscoumacetate in healthy volunteers. *Int J Clin Pharmacol Ther*, 1994, 32, s. 622–624.
- 5 **Sanderson, S. – Emery, J. – Higgins, J.**: CYP2C9 gene variants drug dose, and bleeding risk in warfarin-treated patients: A Hugenet systemic review and meta-analysis. *Genet Med*, 2005, 7, s. 97–104.
- 6 **Wadelius, M. – Chen, L. Y. – Downes, K., et al.**: Common VKORC1 and GGCC polymorphisms associated with warfarin dose. *Pharmacogenomics J*, 2005, 5, s. 262–270.
- 7 **Demirkan, K. – Stephens, M. A. – Newman, K. P., et al.**: Response to warfarin and other oral anticoagulants: effects of disease states. *South Med J*, 2000, 93, s. 448–455.
- 8 **Wells, P. S. – Holbrook, A. M. – Crowther, N. R., et al.**: Interactions of warfarin with drugs and food. *Ann Intern Med*, 1994, 121, s. 676–683.
- 9 **Van de Werf, F. – Brueckmann, M. – Connolly, S. J., et al.**: A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). *Am Heart J*, 2012, 163, s. 931–937.
- 10 **Winkelmayer, W. C. – Liu, J. – Setoguchi, S., et al.**: Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. *Clin J Am Soc Nephrol*, 2011, 6, s. 2662–2668.
- 11 **Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S., et al.**: Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2009, 361, s. 1139–1151.
- 12 **Patel, M. R. – Mahaffey, K. W. – Garg, J., et al.**: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*, 2011, 365, s. 883–891.
- 13 **Granger, C. B. – Alexander, J. H. – McMurray, J. J., et al.**: Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2011, 365, s. 981–992.
- 14 **van Walraven, C. – Jennings, A. – Oake, N., et al.**: Effect of study setting on anticoagulation control: a systematic review and meta-regression. *Chest*, 2006, 129, s. 1155–1166.
- 15 **Baker, W. L. – Cios, D. A. – Sander, S. D., et al.**: Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. *J Manag Care Pharm*, 2009, 15, s. 244–252.
- 16 **DeSantis, G. – Hogan-Schlientz, J. – Liska, G., et al.**: STABLE results: Warfarin home monitoring achieves excellent INR control. *Am J Managed Care*, 2014, 20, s. 202–209.
- 17 **Adam, S. S. – McDuffie, J. R. – Ortel, T. L., et al.**: Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: A systematic review.

18 Morgan, C. L. – McEwan, P. – Tukiendorf, A., et al.: Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. *Thromb Res*, 2009, 124, s. 37–41.

19 Camm, A. J. – Lipp, G. Y. – De Caterina, R., et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. *Eur Heart J*, 2012, 33, s. 2719–2747.

20 January, C. T. – Wann, L. S. – Alpert, J. S., et al.: AHA/ACC/HRS

Guideline for the management of patients with atrial fibrillation. *J Am Coll Cardiol*, 2014, 64, s. e1–e76.

Kompenzace arteriální hypertenze podle medicíny založené na důkazech aneb v jednoduchosti je síla – kazuistika

MUDr. Michaela Šnejdrová, Ph.D.

Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 Cífková, R. – Škodová, Z. – Bruthans, J., et al.: Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. *J Hypertens*, 2010, 28, s. 2196–2203.
- 2 Filipovský, J. – Widimský, J. Jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze, verze 2012: Doporučení České společnosti pro hypertenzi. *Vnitřní Léč*, 2012, 58, s. 785–801.
- 3 Lancia, G. – Tabard, R. – Narkiewicz, K., et al.: 2013 ESH/ESC Guidelines for the management of arterial hypertension. *J Hypertension*, 2013, 31, s. 1281–1357.
- 4 Špinar, J. – Vitovec, J. – Špinarová, L., et al.: Kombinační léčba hypertenze 2015. *Vnitřní Léč*, 2015, 61, s. 458–465.
- 5 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 6 Vitovec, J. – Špinar, J.: Kombinační léčba hypertenze s přihlédnutím k fixním kombinacím. *Kardiolog Rev Int Med*, 2014, 16, s. 444–446.
- 7 James, P. A. – Oparil, S. – Carter, B. L., et al.: 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint national committee (JNC 8). *JAMA*, 2014, 311, s. 507–520.
- 8 Toth, K.: PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus Amlodipine in high risk hypertensive patients). *Am J Cardiovasc Drugs*, 2014, 14, s. 137–145. Erratum in *Am J Cardiovasc Drug*, 2014, 14, s. 239.
- 9 Cífková, R. – Bruthans, J. – Adámková, V.: Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006–2009. Studie Czech post-MONICA. *Cor Vasa*, 2011, 53, s. 4–5.
- 10 Bruthans, J. – Mayer, O. – Jalovcová, M., et al.: State of secondary prevention in Czech coronary patients in the EUROASPIRE IV study. *Cor et Vasa*, 2014, 56, s. 105–112.
- 11 Guidelines on diabetes. Pre-diabetes and cardiovascular disease. *Europ Heart J*, 2007, 28, s. 2–72.
- 12 Expert consensus dokument on beta-adrenergic receptor blockers. *Europ Heart J*, 2004, 25, s. 1341–1362.
- 13 Tesaf, V.: Diuretika v léčbě hypertenze. *Remedia*, 2002, 12, s. 126–131.

Monoklonální protilátky v preventivní kardiologii

MUDr. Eva Tůmová | doc. MUDr. Michal Vrablík, Ph.D.

Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 Catapano, A. L. – Papadopoulos, N.: The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. *Atherosclerosis*, 2013, 228, s. 18–28.
- 2 Seidah, N. G.: PCSK9 as a therapeutic target of dyslipidemia. *Expert Opin Ther Targets*, 2009, 13, s. 19e28.
- 3 Abifadel, M. – Variet, M. – Rabes, J. P., et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet*, 2003, 34, s. 154e6.
- 4 Zhao, Z. – Tuakli-Wosornu, Y. – Legace, T. A., et al.: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. *Am J Hum Genet*, 2006, 79, s. 514e23.
- 5 Cohen, J. C. – Boerwinkle, E. – Mosley, T. H. Jr. – Hobbs, H. H.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med*, 2006, 354, s. 1264e72.
- 6 Cicero, A. F. G. – Colletti, A. – Borghi, C.: Profile of evolocumab and its potential in the treatment of hyperlipidemia. *Drug Design, Development and Therapy*, 2015, 9, s. 3073–3082.
- 7 Stein, E. A. – Wasserman, S. M. – Dias, C., et al.: AMG-145. *Drugs of the Future*, 2013, 38, s. 451–459.
- 8 Dias, C. S. – Shaywitz, A. J. – Wasserman, S. M., et al.: Efficacy, safety, and tolerability of a density lipoprotein cholesterol levels. Results from 2 randomized, double-blind, placebo-controlled, ascending dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. *J Am Coll Cardiol*, 2012, 60, s. 1888–1898.
- 9 Cicero, A. F. – Tartagni, E. – Ertek, S.: Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. *Exp Opin Biol Ther*, 2014, 14, s. 863–868.
- 10 Dias, C. S. – Shaywitz, A. J. – Wasserman, S. M., et al.: Effects of AMG145 on low-monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. *Lancet*, 2012, 380, s. 1995–2006.
- 11 Kohli, P. – Desai, N. R. – Giugliano, R. P., et al.: Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy. *Clin Cardiol*, 2012, 35, s. 385–391.
- 12 Raal, F. – Scot, R. – Somaratne, R., et al.: Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. *Circulation*, 2012, 126, s. 2408–2417.
- 13 Raal, F. J. – Honarpour, N. – Blom, D. J., et al.: for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet*, 2014, 385, s. 341–350.
- 14 Bruckert, E. – Blaha, V. – Stein, E. A., et al.: Trial assessing longterm use of PCSK9 Inhibition in patients with genetic LDL disorders (TAUS-SIG): efficacy and safety in patients with familial hypercholesterolemia receiving lipid apheresis [poster]. American Heart Association Scientific Sessions, 2014, 15–19. 11. 2014, Chicago, USA.
- 15 Sullivan, D. – Olsson, A. G. – Scotty, R., et al.: Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients. The GAUSS Randomized Trial. *JAMA*, 2012, 308, s. 2497–2506.
- 16 Stres, E. – Colquhoun, D. – Sullivan, D., et al.: Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol*, 2014, 63, s. 2541–2548.
- 17 Blom, D. J. – Hala, T. – Bolognese, M., et al.: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. *N Engl J Med*, 2014, 370, s. 1809–1819.
- 18 Amgen. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). Dostupné z: <http://clinicaltrials.gov/show/NCT01764633>, vyhledáno 30. 3. 2016.
- 19 Sabatine, M. S. – Giugliano, R. P. – Wiviott, S. D., et al.: Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med*, 2015, 372, s. 1500–1509.

Fixní dvojkombinace v léčbě arteriální hypertenze se zaměřením na lisinopril/amlodipin (Amesos)

prof. MUDr. Jiří Widimský jr., CSc. III. interní klinika – Centrum pro hypertenzi VFN a 1. LF UK, Praha

- 1 Gusta, A. K. – Arshad, S. – Poulter, N. R.: Compliance, safety and effectiveness of fixed dose combinations of antihypertensive agents: a meta-analysis. *Hypertension*, 2010, 55, s. 399–407.
- 2 Hess, G. – Hill, J. – Lau, H., et al.: Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free combination antihypertensive therapy. *P and T*, 2008, 33, s. 652–665.
- 3 Filipovský, J. – Widimský, J. Jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitřní lékařství*, 2012, 58, s. 785–801.
- 4 Poulter, N. R. – Wedel, H. – Dahlöf, B., et al.: Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). *Lancet*, 2005, 366, s. 907–913.
- 5 Jamerson, K. – Weber, M. A. – Bakris, G. L., et al.: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. *N Engl J Med*, 2008, 359, s. 2417–2428.
- 6 Randomized placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. *Lancet*, 1997, 349, s. 1787–1792.

- 7 Abraham, G. – Bodu, K.: The effect of Lisopress treatment on ambulatory blood pressure and urinary microalbuminuria excretion in patients with hypertension and diabetes. *Hypertension and nephrology*, 2003, 7, s. 13–20.
- 8 Sculpher, M. J. – Poole, L. – Cleland, J., et al.: Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. *Eur J Heart Failure*, 2000, 2, s. 447–454.
- 9 Pilote, L. – Abrahamowicz, M. – Eisenberg, M., et al.: Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. *CMAJ*, 2008, 178, s. 1303–1311.
- 10 Pall, D. – Katona, E. – Juhasz, M., et al.: Prevention of target organ damage with modern antihypertensive agents. *Orv Hetil*, 2006, 147, s. 1505–1511.
- 11 Farsang, C. – Abraham, G., et al.: The effectiveness and safety of Amlodipine-Lisinopril Fix-combination in patients with ESsential hypertension (ALFESS study). *Hypertension and nephrology*, 2009, 13, s. 81–88.
- 12 Krupička, J. – Souček, M. – Wídinský, J. jr.: Projekt Györgyi – neintervenční sledování účinnosti a tolerance léčby hypertenze přípravkem Amesos prostřednictvím 24hodinové kontroly krevního tlaku. *Acta Medicinæ*, 2014, 9, s. 50–55.

Jak můžeme v praxi ověřit komplianci pacienta k antihypertenzní léčbě a jak ji zlepšit

doc. MUDr. Jan Václavík, Ph.D., FESC

Centrum pro hypertenzi, I. Interní klinika – kardiologická, FN a LF UP Olomouc

- 1 Jin, J. – Sklar, G. E. – Min Sen Oh, V. – Chuen Li, S.: Factors affecting therapeutic compliance: A review from the patient's perspective. *Ther Clin Risk Manag*, 2008, 4, s. 269–286.
- 2 Weber, B. – Feihl, F.: Assessment of drug compliance in patients with high blood pressure resistant to antihypertensive therapy. *EuroIntervention*, 2013, 9, s. 29–34.
- 3 Bunker, J. – Callister, W. – Chang, C.-L., et al.: How common is true resistant hypertension? *J Hum Hypertens*, 2011, 25, s. 137–140.
- 4 Fadl Romula, F. E. M. – Hoffmann, P. – Larstorp, A. C., et al.: Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. *Hypertension*, 2014, 63, s. 991–999.
- 5 Hameed, M. A. – Tebbit, L. – Jacques, N., et al.: Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. *J Hum Hypertens*, 2015.
- 6 Ceral, J. – Habrdova, V. – Vorisek, V., et al.: Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. *Hypertens Res*, 2011, 34, s. 87–90.
- 7 Štrajch, B. – Petrák, O. – Zelinka, T., et al.: Precise assessment of non-compliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. *J Hypertens*, 2013, 31, s. 2455–2461.
- 8 Jung, O. – Gechter, J. L. – Tunder, C., et al.: Resistant hypertension? Assessment of adherence by toxicological urine analysis. *J Hypertens*, 2013, 31, s. 766–774.
- 9 Chung, O. – Vongpatanasin, W. – Bonaventura, K., et al.: Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension. *J Hypertens*, 2014, 32, s. 2411–2421.
- 10 Fung, V. – Juany, J. – Brand, R., et al.: Hypertension treatment in a medicare population: Adherence and systolic blood pressure control. *Clin Ther*, 2007, 29, s. 972–984.
- 11 Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 12 Egan, B. M. – Bandyopadhyay, D. – Shaftman, S. R., et al.: Initial monotherapy and combination therapy and hypertension control the first year. *Hypertension*, 2012, 59, s. 1124–1131.
- 13 Gerbino, P. P. – Shoheiber, O.: Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. *Am J Health Syst Pharm*, 2007, 64, s. 1279–1283.
- 14 Lancia, G. – Tabard, R. – Narkiewicz, K., et al.: 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens*, 2013, 31, s. 1281–1357.
- 15 Neutel, J. M. – Smith, D. H. – Reilly, P. A.: The efficacy and safety of telmisartan compared to enalapril in patients with severe hypertension. *Int J Clin Pract*, 1999, 53, s. 175–178.
- 16 Marfatia, R. – White, W. B. – Schumacher, H.: Effects of telmisartan with hydrochlorothiazide versus valsartan with hydrochlorothiazide in patients with moderate-to-severe hypertension. *Int J Hypertens*, 2012, doi: 10.1155/2012/976828, Epub 10. 7. 2012.

Riziko užívání neopioidních analgetik v kardiologii

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Turtle, E. J. – Dear, J. W. – Webb, D. J.: A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects. *Br J Clin Pharmacol*, 2013, 75, s. 1396–1405.
- 2 Ibero, A. – Llopico, J. – Sanchez, M. T.: Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication. *Pharmacoepidemiol Drug Saf*, 2009, 18, s. 417–419.
- 3 Dumler, F.: Dietary sodium intake and arterial blood pressure. *J Ren Nutr*, 2009, 19, s. 57–60.
- 4 Benítez-Camps, M. – Vinyoles-Bargallo, E. – Rebagliato-Nadal, O., et al.: Evaluation of the relationship between effervescent paracetamol and blood pressure: clinical trial. *BMC Cardiovasc Disord*, 2015, 15, s. 167.
- 5 Roberto, G. – Simonetti, M. – Piccinni, C., et al.: Risk of acute cerebrovascular and cardiovascular events among users of acetaminophen or an acetaminophen-codeine combination in a cohort of patients with osteoarthritis: A nested case-control study. *Pharmacotherapy*, 2015, 35, s. 899–909.
- 6 Bombardier, C. – Laine, L. – Reicin, A., et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med*, 2000, 343, s. 1520–1528.
- 7 Bresalier, R. S. – Sander, R. S. – Juan, H., et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. *N Engl J Med*, 2005, 352, s. 1092–1102.
- 8 Silverstein, F. E. – Faich, G. – Goldstein, J. L., et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. *JAMA*, 2000, 284, s. 1247–1255.
- 9 Canon, C. P. – Curtis, S. P. – FitzGerald, G. A., et al.: Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet*, 2006, 368, s. 1771–1781.
- 10 Bhala, N. – Emberson, J. – Merhi, A., et al.: Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*, 2013, 382, s. 769–779.
- 11 Pelletier, J. P. – Martel-Pelletier, J. – Rannou, F. – Cooper, C.: Efficacy and safety of oral NSAIDs and analgesics in the management of osteoarthritis: Evidence from real-life setting trials and surveys. *Semin Arthritis Rheum*, 2016, 45, s. S22–S27.

Akutní perikarditida v EKG obraze

MUDr. Kamila Šolcová | MUDr. Pavel Lang Nemocnice Jablonec nad Nisou, p. o.

- 1 Bělohávek, J., et al.: *EKG v akutní kardiologii: průvodce pro intenzivní péči i rutinní klinickou praxi*. Maxdorf, 2014.
- 2 Grauer, K.: *EKG pocket brain*. 6. vydání, 2014.
- 3 Haberl, R.: *EKG do kapsy*. Grada, 2012.
- 4 Klener, P., et al.: *Vnitřní lékařství*. Galén, 2006.
- 5 Kardioblog, www.kardiologie.blogspot.cz.

Rosuvastatin – možnost bezpečného a rychlého snížení cholesterolu

MUDr. Eva Tůmová, Ph.D. | doc. MUDr. Michal Vrablík, Ph.D.

Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 Crouse, J. R.: An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. *Expert Opin Drug Metab Toxicol*, 2008, 4, s. 1–18.
- 2 Betteridge, J. – Gibbon, M. J. – Sager, P. T.: Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein and low-density lipoprotein cholesterol targets in patients with type 2 diabetes mellitus from the ANDROMEDA study. *Am J Cardiol*, 2007, 100, s. 1245–1248.
- 3 Nissen, S. – Nicholls, S. J. – Spahi, I., et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. *JAMA*, 2006, 295, s. 1556–65.
- 4 Ballantyne, C. M. – Raichlen, J. S. – Nicholls, S. J., et al.: ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. *Circulation*, 2008, 117, s. 2458–2466.
- 5 Rocker, P. M. – Danielson, E. – Fonseca, F. A. H., et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*, 2008, 359, s. 2195–2207.
- 6 Sattar, N. – Preiss, D. – Murray, H. M., et al.: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet*, 2010, 375, s. 735–742.
- 7 Rocker, P. M. – Pradhan, A. – MacFadyen, J. G., et al.: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet*, 2012, 380, s. 565–571.
- 8 Jones, P. H.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). *Am J Cardiol*, 2003, 92, s. 152–160.
- 9 Ridker et al.: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet*, 2012, 380, s. 565–571.
- 10 Bultas, J.: Vzájemné srovnání statinů z pohledu farmakologa. *Remedia*, 2013, 23, s. 143–150.

Fabryho choroba

MUDr. Lubor Goláň II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

- 1 Paleček, T. – Honzík, J. – Poupětová, H., et al.: Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). *J Inher Metab Dis*, 2014, 37, s. 455–460.
- 2 Elliot, P. – Baker, R. – Pasquale, F., et al.: ACES study group. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. *Heart*, 2011, 97, s. 1957–1960.
- 3 Merta, M. – Reiterová, J. – Ledvinová, J., et al.: A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. *Nephrol Dial Transplant*, 2007, 22, s. 179–186.
- 4 Spada, M. – Pagliardini, S. – Yasuda, M., et al.: High incidence of late-onset Fabry disease revealed by newborn screening. *Am J Hum Genet*, 2006, 79, s. 31–40.
- 5 Mechtler, T. P. – Stary, S. – Metz, T. F., et al.: Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. *Lancet*, 2012, 379, s. 335–341.
- 6 Lin, H. Y. – Chong, K. W., et al.: High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population. *Circ Cardiovasc Genet*, 2009, 2, s. 450–456.
- 7 Orteu, C. H. – Jansen, T., et al.: Fabry disease and the skin: data from FOS, the Fabry outcome survey. *Br J Dermatol*, 2007, 157, s. 331–337.
- 8 MacDermot, K. L. D., et al.: Anderson-Fabry disease: clinical manifestations and impact of disease on a cohort of 98 hemizygous males. *J Med Genet*, 2001, 38, s. 750–760.
- 9 Maixnerová, D. – Tesář, V. – Ryšavá, R., et al.: The coincidence of IgA nephropathy and Fabry disease. *BMC Nephrology*, 2013, 14, s. 6.
- 10 Linhart, A. – Paleček, T. – Bultas, J., et al.: New insights in cardiac structural changes in patients with Fabry's disease. *American Heart Journal*, 2000, 139, 6, s. 1101–1108.
- 11 Shah, J. S. – Hughes, D. A. – Sachdev, B., et al.: Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. *Am J Cardiol*, 2005, 96, s. 842–846.
- 12 Rolf, A. – Bottche, T. – Zschiesche, M., et al.: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. *Lancet*, 2005, 366, s. 1794–1796.
- 13 Chamoles, N. – Blanco, M. – Gaglioli, D.: Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. *Clin Chim Acta*, 2001, 308, s. 195–196.
- 14 Thurberg, B. L. – Politei, J. M.: Histologic abnormalities of placental tissues in Fabry disease: a case report and review of the literature. *Hum Pathol*, 2012, 43, s. 610–614.
- 15 Eng, C. M. – Guffon, N. – Wilcox, W. R., et al.: Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry's disease. *N Engl J Med*, 2001, 345, s. 9–16.
- 16 Banikazemi, M. – Bultas, J. – Waldek, S., et al.: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. *Ann Intern Med*, 2007, 146, s. 77–86.
- 17 Schiffmann, R. – Kopp, J. B. – Austin 3rd H. A., et al.: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. *JAMA*, 2001, 285, s. 2743–2749.
- 18 Kampmann, C. – Linhart, A. – Devereux, R. B., et al.: Effect of agalsidase alfa replacement therapy on Fabry disease-related hypertrophic cardiomyopathy: a 12- to 36-month, retrospective, blinded echocardiographic pooled analysis. *Clin Ther*, 2009, 31, s. 1966–1976.
- 19 The FACETS study, www.fabrystudy.com.
- 20 Jain, G. – Warnock, D. G.: Blood pressure, proteinuria and nephropathy in Fabry disease. *Nephron Clin Pract*, 2011, 118, s. 43–48.
- 21 Tahir, H. – Jackson, L. L. – Warnock, D. G.: Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. *J Am Soc Nephrol*, 2007, 18, s. 2609–2617.
- 22 Ojo, A. – Meier-Kriesche, H. U. – Friedman, G., et al.: Excellent outcome of renal transplantation in patients with Fabry's disease. *Transplantation*, 2000, 69, s. 2337–2339.